12th May 2005 14:45
12 May 2005Shire Pharmaceuticals Group plc (the "Company")The Company announces that on 11 May 2005 the following Directors were grantedoptions over ordinary shares of ‚£0.05p each in the Company pursuant to therules of the Shire Pharmaceuticals Group plc 2000 Executive Share Option Scheme(the "Scheme") at a price of ‚£5.585p per share, as follows:Director Number of Shares over which Options granted M Emmens 295,000 A C Russell 195,000 These options are subject to performance criteria and are exercisable at anytime between 3 and 10 years from the date of grant.As a result of this grant, Messrs Emmens and Russell have options over1,557,885 and 916,300 ordinary shares of ‚£0.05p, respectively, pursuant to therules of the Scheme.In addition, on 11 May 2005, rights to acquire ordinary shares of ‚£0.05p eachin the Company at a price of ‚£5.66p were awarded to the following Directorspursuant to the rules of the Shire Pharmaceuticals Group plc Long TermIncentive Plan ("LTIP"):Director Rights to acquire M Emmens 97,468 ordinary shares A C Russell 63,217 ordinary shares The LTIP awards are subject to performance criteria and will becometransferable to the Directors in 2009. At the discretion of the RemunerationCommittee, the awards may be satisfied with ordinary shares or cash.As a result of this award Messrs Emmens and Russell have the right to acquire283,687 and 203,592 ordinary shares of ‚£0.05p, respectively, pursuant to therules of the LTIP.As the Company has been in possession of unpublished, price-sensitiveinformation since the publication of its 2004 results, these annual awards andgrants have been made at the earliest opportunity following the publication ofall such information.T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing projects and marketing products in theareas of central nervous system (CNS), gastrointestinal (GI), and renaldiseases. Shire has operations in the world's key pharmaceutical markets (US,Canada, UK, France, Italy, Spain and Germany) as well as a specialist drugdelivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com.Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire